Cargando…
JAK抑制剂芦可替尼治疗中国骨髓纤维化患者的疗效和安全性:A2202随访一年结果
OBJECTIVE: To evaluate the efficacy and safety of ruxolitinib in Chinese myelofibrosis patients. METHODS: This study enrolled 63 Chinese patients (32 males and 31 females) in total, whose median age was 55 (25–79) years. The initial dose of ruxolitinib was 30mg/d (25 patients) with a baseline of PLT...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364878/ https://www.ncbi.nlm.nih.gov/pubmed/27801315 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.10.007 |
Ejemplares similares
-
芦可替尼治疗慢性粒-单核细胞白血病一例
Publicado: (2019) -
基于二代测序技术分析骨髓纤维化患者基因突变对芦可替尼疗效的影响
Publicado: (2022) -
芦可替尼联合泼尼松、沙利度胺和达那唑治疗骨髓纤维化的探索性研究
Publicado: (2019) -
芦可替尼挽救性治疗难治性急慢性移植物抗宿主病的疗效及安全性观察
Publicado: (2018) -
基于416例Ⅰ期NSCLC肺叶切除术后随访结果探讨早期NSCLC术后随访策略
Publicado: (2018)